Usted buscó: cervixcancer (Danés - Inglés)

cervixcancer
cervical carcinoma

dosering: cervixcancer
dosage: cervical carcinoma

kombinationsbehandling (cervixcancer)
combination therapy (cervical carcinoma)

cervixcancer første dosis
initial dose

instruktioner for forberedelse til intravenøs administration for cervixcancer
instructions for preparation for intravenous administration for cervical cancer

cin 3 og ais er blevet accepteret som umiddelbare forstadier til invasiv cervixcancer.
cin 3 and ais have been accepted as immediate precursors of invasive cervical cancer.

ais, cervixcancer, vin 2/3, vain 2/3, vulvacancer og vaginal cancerα
ais, cervical cancer, vin 2/3, vain 2/3, vulvar cancer, and vaginal cancerα

ved behandling af cervixcancer gives topotecan eagle sammen med et andet lægemiddel, der kaldes cisplatin.
for cervical cancer topotecan eagle will be used with another medicine called cisplatin.

hvis behandlingen med cisplatin ophører, er der utilstrækkelige data om fortsat behandling med topotecanmonoterapi til patienter med cervixcancer.
if cisplatin is discontinued, there are insufficient data regarding continuing monotherapy with topotecan in patients with cervical cancer.

hvis behandlingen med cisplatin ophører, er der utilstrækkelige data til at underbygge fortsat monoterapi med topotecan til patienter med cervixcancer.
if cisplatin is discontinued, there are insufficient data regarding continuing monotherapy with topotecan in patients with cervical cancer.

måcellet lungecancer, der er kommet tilbage efter kemoterapi avanceret cervixcancer, når kirurgi eller strålebehandling ikke er mulig.
mall cell lung cancer that has come back after chemotherapy advanced cervical cancer when surgery or radiotherapy are not possible.

topotecan i kombination med cisplatin er indiceret til behandling af patienter med cervixcancer, som recidiverer efter strålebehandling eller til patienter i sygdomsstadie ivb.
topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage ivb disease.

bivirkningsprofilen fra kliniske studier af topotecan, givet i kombination med cisplatin mod cervixcancer, er i overensstemmelse med hvad der er set ved monoterapi med topotecan.
the adverse event profile for topotecan when given in combination with cisplatin in the cervical cancer clinical trials is consistent with that seen with topotecan monotherapy.

i de kliniske studier af kombinationsbehandling med topotecan og cisplatin til behandling af cervixcancer blev behandlingen kun initieret hos patienter med serumcreatinin ≤ 132 μmol /l.
in clinical studies with topotecan in combination with cisplatin for the treatment of cervical cancer, therapy was only initiated in patients with serum creatinine less than or equal to 132 μmol/l.

i kliniske studier af kombinationsbehandling med topotecan og cisplatin til behandling af cervixcancer blev behandlingen kun initieret for patienter med serumkreatinin ≤ 1, 5 mg/ dl.
combination therapy (cervical carcinoma) in clinical studies with topotecan in combination with cisplatin for the treatment of cervical cancer, therapy was only initiated in patients with serum creatinine less than or equal to 1.5 mg/ dl.

hpv type 16 og 18 er årsagen til omkring 70% af alle tilfælde af cervixcancer, og hpv type 6 og 11 er årsagen til omkring 90% af alle tilfælde af kondylomer.
hpv types 16 and 18 cause approximately 70% of cervical cancers and hpv types 6 and 11 cause approximately 90% of genital warts.

kombinationsterapi (cervixcancer):i kliniske studier af kombinationsbehandling med topotecan og cisplatin til behandling af cervixcancer blev behandlingen kun initieret for patienter med serumkreatinin 1, 5 mg/dl.
3 combination therapy (cervical carcinoma) in clinical studies with topotecan in combination with cisplatin for the treatment of cervical cancer, therapy was only initiated in patients with serum creatinine less than or equal to 1.5 mg/dl.

i et randomiseret, sammenlignende fase iii-studie, udført af gynaecological oncology group (gog 0179), blev topotecan + cisplatin (n = 147) sammenlignet med cisplatin alene (n = 146) for behandling af histologisk bekræftet, persisterende, recidiverende eller stadium ivb-cervixcancer, hvor kurativ intenderet behandling med kirurgi og/eller stråleterapi ikke var vurderet hensigtsmæssig.
in a randomised, comparative phase iii trial conducted by the gynaecological oncology group (gog 0179), topotecan plus cisplatin (n = 147) was compared with cisplatin alone (n = 146) for the treatment of histologically confirmed persistent, recurrent or stage ivb carcinoma of the cervix where curative treatment with surgery and/or radiation was not considered appropriate.